Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.

Wigal T, Brams M, Gasior M, Gao J, Giblin J.

Postgrad Med. 2011 Mar;123(2):169-76. doi: 10.3810/pgm.2011.03.2275.

PMID:
21474905
3.

Duration of effect of oral long-acting stimulant medications for ADHD throughout the day.

Brams M, Moon E, Pucci M, López FA.

Curr Med Res Opin. 2010 Aug;26(8):1809-25. doi: 10.1185/03007995.2010.488553. Review.

PMID:
20491612
4.

Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.

Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P.

Curr Med Res Opin. 2014 Aug;30(8):1673-85. doi: 10.1185/03007995.2014.904772. Epub 2014 Apr 15. Review.

PMID:
24627974
5.

A systematic review of the safety of lisdexamfetamine dimesylate.

Coghill DR, Caballero B, Sorooshian S, Civil R.

CNS Drugs. 2014 Jun;28(6):497-511. doi: 10.1007/s40263-014-0166-2. Review.

6.

The use of lisdexamfetamine dimesylate for the treatment of ADHD.

Childress AC, Sallee FR.

Expert Rev Neurother. 2012 Jan;12(1):13-26. doi: 10.1586/ern.11.175. Review.

PMID:
22243042
7.

Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder.

Steer C, Froelich J, Soutullo CA, Johnson M, Shaw M.

CNS Drugs. 2012 Aug 1;26(8):691-705. doi: 10.2165/11634340-000000000-00000. Review.

PMID:
22762726
8.

Lisdexamfetamine: a prodrug for the treatment of attention-deficit/hyperactivity disorder.

Popovic B, Bhattacharya P, Sivaswamy L.

Am J Health Syst Pharm. 2009 Nov 15;66(22):2005-12. doi: 10.2146/ajhp080353. Review.

PMID:
19890083
9.

Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.

Childress AC.

Adv Ther. 2012 May;29(5):385-400. doi: 10.1007/s12325-012-0020-1. Epub 2012 May 18. Review.

PMID:
22610723
10.

Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder.

Brams M, Mao AR, Doyle RL.

Postgrad Med. 2008 Sep;120(3):69-88. doi: 10.3810/pgm.2008.09.1909. Review.

PMID:
18824827
11.

Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.

Dew RE, Kollins SH.

Expert Opin Pharmacother. 2010 Dec;11(17):2907-13. doi: 10.1517/14656566.2010.531009. Epub 2010 Oct 28. Review.

PMID:
20979573
12.

An update on lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder.

Wigal SB, Raja P, Shukla A.

Expert Opin Pharmacother. 2013 Jan;14(1):137-45. doi: 10.1517/14656566.2013.754013. Epub 2012 Dec 14. Review.

PMID:
23241144
13.

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.

Findling RL.

Clin Ther. 2008 May;30(5):942-57. doi: 10.1016/j.clinthera.2008.05.006. Review.

PMID:
18555941
14.

Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder.

Cowles BJ.

Ann Pharmacother. 2009 Apr;43(4):669-76. doi: 10.1345/aph.1L521. Epub 2009 Mar 24. Review.

PMID:
19318601
15.

[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].

Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.

Encephale. 2005 May-Jun;31(3):337-48. Review. French.

PMID:
16142049
16.
17.

Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD.

Maneeton N, Maneeton B, Suttajit S, Reungyos J, Srisurapanont M, Martin SD.

Drug Des Devel Ther. 2014 Oct 3;8:1685-93. doi: 10.2147/DDDT.S68393. eCollection 2014. Review.

18.

Predicted effect size of lisdexamfetamine treatment of attention deficit/hyperactivity disorder (ADHD) in European adults: Estimates based on indirect analysis using a systematic review and meta-regression analysis.

Fridman M, Hodgkins PS, Kahle JS, Erder MH.

Eur Psychiatry. 2015 Jun;30(4):521-7. doi: 10.1016/j.eurpsy.2015.01.001. Epub 2015 Feb 25. Review.

PMID:
25725594
19.

Lisdexamfetamine: a prodrug stimulant for ADHD.

Howland RH.

J Psychosoc Nurs Ment Health Serv. 2008 Aug;46(8):19-22. Review.

PMID:
18777964
20.

Supplemental Content

Support Center